



JC10 Rec'd PCT/PTO 08 JUL 2005

pt

THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Del Soldato

Group Art Unit: Unknown

#5

Patent Application Serial No.: 10/509,675 Examiner: Unknown

Filed: October 8, 2004

Attorney Docket No.: 026220-00055

For: Drugs for the Arthritis Treatment

July 8, 2005

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 C.F.R. §§1.56, 1.97, and 1.98, the applicant respectfully directs the attention of the U.S. Patent and Trademark Office to the documents listed on the attached Forms PTO-SB/08a and SB/08b.

GB 1,195,628 (Reference AR) is the English language equivalent of FR 1,574,570, which the applicant does not include. GB 1,519,811 (Reference AS) is the English language equivalent of DE 2,537,070, which the applicant also does not include.

The applicant respectfully requests that the information be considered during the prosecution of this application, the items be made of record therein, and that the references appear among the "References Cited" on any patent issuing therefrom. The applicant further requests that the attached Forms PTO-SB/08a and SB/08b be initialed and return to the undersigned.


This Information Disclosure Statement is filed pursuant to 37 C.F.R. §1.97(b)(3), *i.e.*, before the mailing of a first office action on the merits. Therefore, the applicant

U.S. Patent Application No.: 10/509,675
Inventor(s): Del Soldato
Attorney Docket No.: 026220-00055

believes that no fee is due for the consideration of this information. The Commissioner is authorized to charge any fee deficiencies, or credit any over-payments, to Deposit Account No. 01-2300, referencing Attorney Docket No. 026220-00055.

Respectfully submitted,

ARENT FOX PLLC



Gautam Prakash, Ph.D.
Registration No.: 53,481
Direct Telephone No.: 202-857-6057

Customer No.: **004372**

1050 Connecticut Avenue, N.W.
Washington, D.C. 20036-5339

Telephone No.: 202-857-6000
Facsimile No.: 202-857-6395

/GP



PTO/SB/08b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Form PTO/SB/08b				Application Number	10/509,675
				Filing Date	October 8, 2004
				First Named Inventor	DEL SOLDATO
				Art Unit	
				Examiner Name	
Sheet	1	of	1	Attorney Docket Number	026220-00055

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AT	RASHAD <i>et al.</i> , "Effect of Non-Steroidal Anti-Inflammatory Drugs on the Course of Osteoarthritis", <i>Lancet Ltd.</i> 519-522, 1989.	
	AU	FELISAZ <i>et al.</i> , "Stimulating effect of diacerein on TGF- β 1 and β 2 expression in articular chondrocytes cultured with and without interleukin-1", <i>Osteoarthritis and Cartilage</i> 7, 255-267, 1999.	
	AV	BOUMEDIENE <i>et al.</i> , "Decrease of cartilage transforming growth factor- β receptor II expression in the rabbit experimental osteoarthritis-potential role in cartilage breakdown", <i>Osteoarthritis and Cartilage</i> 6, 146-149, 1998.	
	AW	CHOY <i>et al.</i> , "Therapeutic Benefit of Blocking Interleukin-6 Activity With an Anti-Interleukin-6 Receptor Monoclonal Antibody in Rheumatoid Arthritis", <i>Arthritis & Rheumatism</i> 46(12), 3143-3150, 2002.	
	AX	BENYA <i>et al.</i> , "The Progeny of Rabbit Articular Chondrocytes Synthesize Collagen Types I and III and Type I Trimer, but Not Type II. Verifications by Cyanogen Bromide Peptide Analysis", <i>Biochemistry</i> 16(5), 865-872, 1977.	
	AY	JENNINGS <i>et al.</i> , "Comparison of the Biological Actions of TGF Beta-1 and TGF Beta-2: Differential Activity in Endothelial Cells", <i>J. Cellular Physiol.</i> 137, 167-172, 1988.	
	AZ	<u>Martindale The Extra Pharmacopoeia</u> , Thirty-first Edition (Reynolds, J.E. Ed.), 1996, pp. 11-13	
	BA	<u>Martindale The Extra Pharmacopoeia</u> , Thirty-first Edition (Reynolds, J.E. Ed.), 1996pp. 299-300	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code. ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached. AB indicates that only an English language abstract is attached.